Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Core Insights - Genmab is presenting 14 abstracts on epcoritamab at the 30th European Hematology Association Congress, showcasing its development across various patient populations and treatment settings [1][4] - Epcoritamab is a T-cell engaging bispecific antibody designed for treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) [6][7] Development Program - The abstracts include data from Phase 1/2 trials evaluating epcoritamab in combination with other therapies for relapsed/refractory DLBCL and previously untreated DLBCL [2][4] - Key trials include EPCORE NHL-2 and NHL-5, focusing on combinations with rituximab and polatuzumab vedotin [2][5] Presentation Details - Oral presentations will occur on June 15, 2025, featuring significant findings from the EPCORE NHL-2 and NHL-5 trials [5] - Additional results from NHL-1 and NHL-3 trials will be presented as posters, highlighting three years of follow-up data [2][5] Regulatory Status - Epcoritamab has received regulatory approval in specific lymphoma indications in the U.S., Japan, and the EU, and is co-developed with AbbVie [7][10] - The companies are pursuing further international regulatory approvals for additional indications [7] Future Directions - Genmab and AbbVie are conducting five ongoing Phase 3 trials to evaluate epcoritamab's efficacy as a monotherapy and in combination therapies across various hematologic malignancies [8][9] - The companies aim to establish epcoritamab as a core therapy for B-cell malignancies [4][8]